Condition or disease:MSS Metastatic Colorectal Carcinoma (mCRC)~Phase:Phase 2~Intervention/treatment:~Radiation: hypofractionation radiotherapy~Drug: sintilimab, GM-CSF , Fruquintinib
To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)